^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ThermoDox (lyso-thermosensitive liposomal doxorubicin)

i
Other names: LTLD, LTSDEL
Associations
Trials
Company:
Imunon
Drug class:
Topoisomerase II inhibitor, DNA intercalator, Reactive oxygen species stimulant, RNA synthesis inhibitor
Related drugs:
Associations
Trials
8ms
Modulated Electro-Hyperthermia Accelerates Tumor Delivery and Improves Anticancer Activity of Doxorubicin Encapsulated in Lyso-Thermosensitive Liposomes in 4T1-Tumor-Bearing Mice. (PubMed, Int J Mol Sci)
In this study, we investigated whether mEHT accelerates the tumor-specific delivery of doxorubicin (DOX) from lyso-thermosensitive liposomal doxorubicin (LTLD) and improves its anticancer efficacy in mice bearing a triple-negative breast cancer cell line (4T1)...The body weight loss was similar in all mice treated with any DOX formulation, suggesting no difference in toxicity. In conclusion, LTLD combined with mEHT represents a novel approach for DOX delivery into cancer tissue.
Preclinical • Journal
|
CASP3 (Caspase 3)
|
pegylated liposomal doxorubicin • ThermoDox (lyso-thermosensitive liposomal doxorubicin)
1year
Data demonstrating the in vivo anti-tumor efficacy of thermosensitive liposome formulations of a drug combination in pre-clinical models of breast cancer. (PubMed, Data Brief)
Our group previously developed and characterized a thermosensitive liposome formulation of the heat shock protein 90 inhibitor alvespimycin as a companion therapeutic to a thermosensitive liposome formulation equivalent in composition to ThermoDox (i.e., ThermoDXR), with the goal of increasing the therapeutic index of doxorubicin as the combination was revealed to be highly synergistic in a panel of human breast cancer cell lines including MDA-MB-231 (Dunne et al., 2019). The data presented here further describes the effect of the doxorubicin (DXR) and alvespimycin (ALV) combination in vitro and in vivo. Specifically, the combination effect in mouse breast cancer 4T1 cells and the in vivo efficacy of this heat-activated chemotherapy combination in both immunocompromised (MDA-MB-231 tumor bearing female SCID mice) and immunocompetent (4T1 tumor bearing female BALB/c mice) models of breast cancer.
Preclinical • Journal
|
doxorubicin hydrochloride • ThermoDox (lyso-thermosensitive liposomal doxorubicin)
1year
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound. (PubMed, BMC Cancer)
This early phase study builds on previous work targeting tumours in the liver to investigate whether enhancement of chemotherapy delivery using ultrasound-mediated hyperthermia can be translated to the stroma-dense environment of pancreatic ductal adenocarcinoma. If successful, it could herald a new approach towards managing these difficult-to-treat tumours.
P1 data • Journal
|
doxorubicin hydrochloride • ThermoDox (lyso-thermosensitive liposomal doxorubicin)
almost4years
Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in de novo stage IV breast cancer patients: study protocol of the i-GO study. (PubMed, BMJ Open)
This is to be achieved by combining Lyso-Thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox, Celsion Corporation, Lawrenceville, NJ, USA) with mild local hyperthermia, induced by Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU). Results will be published in an academic peer-reviewed journal. NCT03749850, EudraCT 2015-005582-23.
Clinical • P1 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
ThermoDox (lyso-thermosensitive liposomal doxorubicin) • cyclophosphamide intravenous • doxorubicin liposomal